hC Bioscience Announces Extension of Series A to $40 Million Expansion of syndicate enables broadening of platforms, expansion of pipeline and extension of runway   Lead platform centered on engineered tRNAs for human diseases caused by premature termination...

hC Bioscience Appoints Brad Margus to its Board of Directors CAMBRIDGE, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- hC Bioscience, Inc., a company developing first-in-class tRNA-based therapeutics targeting protein dysfunction in genetically defined diseases,...

hC Bioscience Expands Leadership and Research & Development Teams CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- hC Bioscience, Inc., a biotech company developing first-in-class tRNA-based therapeutics targeting protein dysfunction in genetically defined...

hC Bioscience Announces $24 Million Series A Financing to Develop Innovative Pipeline of Protein-Editing Therapies Combining a strong syndicate of investors, seasoned management, and exemplary scientific advisorshC Bioscience is developing a new class of therapy for genetically defined diseases based on more than...